See more : Filament Health Corp. (FH.NE) Income Statement Analysis – Financial Results
Complete financial analysis of Omnicell, Inc. (OMCL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Omnicell, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- UL Solutions Inc. (ULS) Income Statement Analysis – Financial Results
- Unjha Formulations Limited (UNJHAFOR.BO) Income Statement Analysis – Financial Results
- Kaofu Chemical Corporation (4773.TWO) Income Statement Analysis – Financial Results
- Samsung C&T Corporation (02826K.KS) Income Statement Analysis – Financial Results
- Lushang Health Industry Development Co.,Ltd. (600223.SS) Income Statement Analysis – Financial Results
Omnicell, Inc. (OMCL)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.omnicell.com
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.15B | 1.30B | 1.13B | 892.21M | 897.03M | 787.31M | 716.17M | 692.62M | 484.56M | 440.90M | 380.59M | 314.03M | 245.54M | 222.41M | 213.46M | 251.87M | 213.08M | 154.71M | 121.52M | 123.94M | 102.13M | 87.69M | 86.90M | 67.37M |
| Cost of Revenue | 647.18M | 706.96M | 577.37M | 478.92M | 460.12M | 414.98M | 394.08M | 378.82M | 236.63M | 207.04M | 177.19M | 143.47M | 109.75M | 104.49M | 108.24M | 123.23M | 99.77M | 69.19M | 54.51M | 52.03M | 42.46M | 36.42M | 32.77M | 26.58M |
| Gross Profit | 499.93M | 588.99M | 554.65M | 413.29M | 436.91M | 372.33M | 322.09M | 313.80M | 247.93M | 233.86M | 203.40M | 170.55M | 135.78M | 117.92M | 105.22M | 128.63M | 113.31M | 85.52M | 67.01M | 71.91M | 59.67M | 51.27M | 54.13M | 40.79M |
| Gross Profit Ratio | 43.58% | 45.45% | 49.00% | 46.32% | 48.71% | 47.29% | 44.97% | 45.31% | 51.17% | 53.04% | 53.44% | 54.31% | 55.30% | 53.02% | 49.29% | 51.07% | 53.18% | 55.28% | 55.14% | 58.02% | 58.42% | 58.47% | 62.29% | 60.55% |
| Research & Development | 97.12M | 104.97M | 75.72M | 70.16M | 68.64M | 64.84M | 66.02M | 57.80M | 35.16M | 27.80M | 29.11M | 23.73M | 22.04M | 21.01M | 17.57M | 18.20M | 15.05M | 11.22M | 9.61M | 9.11M | 8.95M | 9.97M | 11.03M | 11.27M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 138.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 434.59M | 486.34M | 389.43M | 307.61M | 289.92M | 263.10M | 250.31M | 249.52M | 167.58M | 156.48M | 139.00M | 119.75M | 97.52M | 86.23M | 85.67M | 93.10M | 80.04M | 65.04M | 59.70M | 52.08M | 42.78M | 44.77M | 43.68M | 46.14M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -178.00K | -99.00K | 0.00 | 0.00 | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 534.80M | 591.31M | 465.15M | 377.77M | 358.56M | 327.94M | 316.33M | 307.32M | 202.74M | 184.28M | 168.10M | 143.47M | 119.56M | 107.23M | 103.24M | 111.29M | 95.09M | 76.27M | 69.31M | 61.19M | 51.73M | 54.74M | 54.71M | 57.41M |
| Cost & Expenses | 1.18B | 1.30B | 1.04B | 856.68M | 818.68M | 742.92M | 710.41M | 686.14M | 439.37M | 391.32M | 345.29M | 286.94M | 229.31M | 211.72M | 211.47M | 234.53M | 194.86M | 145.45M | 123.82M | 113.22M | 94.19M | 91.16M | 87.48M | 83.99M |
| Interest Income | 0.00 | 130.00K | 23.50M | 6.18M | 4.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.00K | 77.00K | 266.00K | 424.00K | 619.00K | 3.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 130.00K | 22.39M | 2.10M | 5.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 122.00K | 29.00K | 62.00K | 4.00K | 15.00K | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 95.56M | 99.17M | 84.93M | 71.60M | 64.12M | 51.35M | 51.51M | 58.36M | 25.64M | 20.27M | 18.37M | 13.33M | 7.98M | 8.62M | 9.43M | 8.95M | 4.60M | 3.72M | 4.20M | 4.09M | 3.50M | 3.02M | 3.72M | 3.66M |
| EBITDA | 60.69M | 96.85M | 174.44M | 107.12M | 78.35M | 95.74M | 62.66M | 64.84M | 71.88M | 69.86M | 53.66M | 40.45M | 24.13M | 18.58M | 10.64M | 29.69M | 22.83M | 12.97M | 2.15M | 15.02M | 11.44M | -5.90M | 1.90M | -12.97M |
| EBITDA Ratio | 5.29% | 7.47% | 15.41% | 12.01% | 15.88% | 12.16% | 8.00% | 9.36% | 13.91% | 11.25% | 9.27% | 8.62% | 6.66% | 5.13% | 1.30% | 5.54% | 10.73% | 8.33% | 1.85% | 12.06% | 12.14% | 2.28% | 3.44% | -14.94% |
| Operating Income | -34.87M | -2.32M | 89.51M | 35.53M | 78.35M | 44.39M | 5.75M | 6.48M | 48.63M | 49.58M | 35.30M | 27.08M | 16.22M | 9.53M | 669.00K | 17.34M | 18.22M | 9.26M | -2.71M | 10.55M | 6.98M | -5.90M | -430.00K | -19.53M |
| Operating Income Ratio | -3.04% | -0.18% | 7.91% | 3.98% | 8.73% | 5.64% | 0.80% | 0.94% | 10.04% | 11.25% | 9.27% | 8.62% | 6.61% | 4.28% | 0.31% | 6.88% | 8.55% | 5.98% | -2.23% | 8.51% | 6.84% | -6.73% | -0.49% | -29.00% |
| Total Other Income/Expenses | 14.76M | -130.00K | -23.50M | -6.18M | -4.42M | -8.78M | -6.63M | -8.43M | -2.39M | -1.08M | -270.00K | -51.00K | -133.00K | 431.00K | 523.00K | 3.38M | 6.05M | 1.91M | 651.00K | 379.00K | 565.00K | 875.00K | -577.00K | -1.16M |
| Income Before Tax | -20.11M | -2.45M | 66.01M | 29.35M | 73.93M | 35.62M | -879.00K | -1.95M | 46.24M | 48.50M | 35.03M | 27.03M | 16.09M | 9.96M | 1.19M | 20.72M | 24.28M | 11.17M | -2.05M | 10.93M | 7.55M | -5.03M | -1.01M | -20.69M |
| Income Before Tax Ratio | -1.75% | -0.19% | 5.83% | 3.29% | 8.24% | 4.52% | -0.12% | -0.28% | 9.54% | 11.00% | 9.20% | 8.61% | 6.55% | 4.48% | 0.56% | 8.23% | 11.39% | 7.22% | -1.69% | 8.82% | 7.39% | -5.73% | -1.16% | -30.71% |
| Income Tax Expense | 263.00K | -8.10M | -11.84M | -2.85M | 12.60M | -2.11M | -21.48M | -2.55M | 15.48M | 17.99M | 11.05M | 10.87M | 5.70M | 5.07M | 748.00K | 8.00M | -19.02M | 804.00K | 20.00K | 324.00K | 242.00K | 10.00K | 160.00K | 100.00K |
| Net Income | -20.37M | 5.65M | 77.85M | 32.19M | 61.34M | 37.73M | 20.61M | 603.00K | 30.76M | 30.52M | 23.98M | 16.16M | 10.39M | 4.89M | 444.00K | 12.72M | 43.30M | 10.37M | -2.07M | 10.60M | 7.31M | -5.04M | -1.17M | -20.79M |
| Net Income Ratio | -1.78% | 0.44% | 6.88% | 3.61% | 6.84% | 4.79% | 2.88% | 0.09% | 6.35% | 6.92% | 6.30% | 5.15% | 4.23% | 2.20% | 0.21% | 5.05% | 20.32% | 6.70% | -1.71% | 8.55% | 7.15% | -5.75% | -1.34% | -30.86% |
| EPS | -0.45 | 0.13 | 1.79 | 0.76 | 1.48 | 0.96 | 0.81 | 0.27 | 0.86 | 0.86 | 0.69 | 0.49 | 0.31 | 0.15 | 0.01 | 0.40 | 1.35 | 0.38 | -0.08 | 0.43 | 0.32 | -0.23 | -0.11 | -12.20 |
| EPS Diluted | -0.45 | 0.12 | 1.62 | 0.74 | 1.43 | 0.93 | 0.79 | 0.26 | 0.84 | 0.83 | 0.67 | 0.47 | 0.30 | 0.15 | 0.01 | 0.38 | 1.28 | 0.36 | -0.08 | 0.38 | 0.29 | -0.23 | -0.11 | -12.20 |
| Weighted Avg Shares Out | 45.21M | 44.40M | 43.48M | 42.58M | 41.46M | 39.24M | 37.48M | 36.16M | 35.86M | 35.65M | 34.74M | 33.31M | 33.12M | 32.65M | 31.69M | 32.08M | 32.08M | 27.35M | 25.91M | 24.85M | 22.75M | 21.73M | 10.31M | 1.70M |
| Weighted Avg Shares Out (Dil) | 45.21M | 45.89M | 47.94M | 43.74M | 42.94M | 40.56M | 38.71M | 36.86M | 36.72M | 36.62M | 35.78M | 34.21M | 34.10M | 33.51M | 32.06M | 33.11M | 33.82M | 28.90M | 25.91M | 27.72M | 25.32M | 21.73M | 10.31M | 1.70M |
New Strong Buy Stocks for October 4th
Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer
Should You Continue to Retain OMCL Stock in Your Portfolio Now?
Earnings Estimates Moving Higher for Omnicell (OMCL): Time to Buy?
Omnicell (OMCL) Introduces Central Med Automation Service
Omnicell Announces Central Med Automation Service
Omnicell, Inc. (OMCL) Q2 2024 Earnings Call Transcript
Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?
Source: https://incomestatements.info
Category: Stock Reports